Michael Hecht Olsen

MD, PhD, DMSc

20112019
If you made any changes in Pure these will be visible here soon.

Personal profile

Curriculum

CV Michael Hecht Olsen

Education
1966: Borne December 1st.
1992: Medical degree, Grade 11.1, The University of Copenhagen
1999: PhD at University of Copenhagen:
”A Vascular relationship between hypertension and insulin resistance”
2007: Specialist in Cardiology April 2007
2007-11:Chief physician in Cardiology with 50 % research at Dept. Internal Medicine,
Glostrup Hospital.
2008-: Associate professor, University of Copenhagen
2009: DMSc at University of Copenhagen: “New Cardiovascular Risk Markers-
Do they Improve Risk Prediction and Influence Treatment Indication and Choice?”
2011 January: Associate professor, University of Southern Denmark
2011 August: Professor in Hypertension, University of Southern Denmark
2011 August: Chief physician, Hypertension Clinic, Department of Endocrinology, Odense University Hospital.
2012 April: Professor extraordinaire, Hypertension in Africa Research Team (HART)
School for Physiology, Nutrition and Consumer Sciences, North-West University, Potchefstroom, South Africa
Tutoring
2003-07:PhD-tutor for Marina K. Christensen, ”The relationship of collagen markers to the
cardiovascular system”, Dept. of Clinical Physiology and Nuclear Medicine,
Glostrup Hospital. Defended and aquired 2007
2009: Member of the assessment committee for the PhD of Michael Nyrup Præstholm,
“Essential hypertension: vascular and diagnostic aspects with potential influence on patient management”
2008-11:PhD-tutor for Thomas Sehestedt, The importance of subclinical cardiovascular
damage and new risk markers for risk stratification especially in subjects with high
normal blood pressure”, Dept. of Internal Medicine, Glostrup Hospital.
Defended and acquired February 4th 2011.
2008-12:PhD-tutor for Stig Lyngbæk, “SuPAR – a new marker for development of
cardiovascular disease”, Dept. of Internal Medicine, Glostrup Hospital
2008-12:PhD-tutor for Camilla Lund Søraas, ”The prognostic importance of left ventricular hypertrophy after coronary revascularization, Dept. of Cardiology, Ullevaal Universitets Hospital, Oslo with professor Sverre E. Kjeldsen as main tutor
2009-14:PhD-tutor for Julie Vishram, “The prognostic justification of the metabolic syndrome and the prognostic importance of systolic versus diastolic blood pressure with increasing age”, Dept. of Internal Medicine, Glostrup Hospital. Defended and aquired 2014.
2010-14:PhD-tutor for Kristian Hvidt, “Blood pressure and central vascular stiffness in obese children. Relationships to the metabolic syndrome and subclinical cardiovascular damage. Effect of weight reduction”. Dept. of Internal Medicine, Holbæk Hospital. Defended and aquired 2014
2011-: PhD-tutor for Adam Blyme, “Markers of Left ventricular Hypertrophy - A Study in Patients with Aortic Valve Stenosis and in the General Population”. Dept. of Internal Medicine, Glostrup Hospital. Started September 2011.
2011: Member of the assessment committee for the PhD of Skjalg Hassellunds Ph.d.-opgave ved Oslo Universitet: “Effects of Anthocyanin Supplementation on Pathophysiological Markers of Cardiovascular Disease”
2011: Tutor for Henrik Steglich-Arnholm OSVAL II project: ”The impact of obesity on the prognostic importance of N-terminal pro brain natriuretic peptide, and other markers, in apparently healthy people”. Department of Internal Medicine, Glostrup Hospital. Passed with 12.
2011: President for the assessment committee for employment of research and development nurse in cardiology at OUH
2011-: PhD-tutor for Britta Frederiksen-Møller, ”SYDHOP – SYDdansh Hypertension and Oedema in Preeclampsia study hospital Fyn” Department of Gynecology/obstetric, OUH. Registered 2011.
2011-12:Tutor for Thomas Sehested OSVAL II project: “Simple cardiovascular risk stratification tools and anthropometric measures. The MORGAM project”. Department of Internal Medicine, Glostrup Hospital. Passed with 12.
2012-: Tutor for Kasper Bostlund Assersen, One year, pregraduate researc-education with the project: ”Mechanisms behind elevated blood pressure: Local renal blood flow in hypertension”. Department of Nuclear Medicine, OUH. Registered February 2012.
2012-: PhD-tutor for Sara Vikström, ”Subclinical Target Organ Damage – Markers of Individual Cardiovascular Susceptibility to the Harmful Effect of Risk Factors (ATOMICS)” Department of Endocrinology, OUH. Registered March 2012.
2012-: PhD-tutor for Mette Hjortdal Sørensen, ”Biomarkers and coronary artery calcium Inflammatory- and Calcium-phosphate-metabolism-markers related to coronary artery calcium” Department of Cardiology, OUH. Registered May 2012.
2012-: PhD-tutor for Jacob Volmer Stidsen, ”Individually tailored treatment in T2D” Department of Endocrinology, OUH. Registered March 2012.
2012-: PhD-tutor for Marie K. Blicher, ”Catheter based Renal denervation in patients with Resistant hypertension – Effects on kidney, Vasculature and Insulin SEnsitivity (REVISE)” Department of Endocrinology, OUH. Registered September 2012.
2014- PhD-tutor for Manan Pareek, “Detection of Early Atherosclerosis and Arteriosclerosis using Biomarkers and PET/CT (DETECT) in Healthy Controls and Patients with Hypertension, Type 2 Diabetes, or Carotid Artery Stenosis”. Department of Endocrinology, OUH. Registered March 2014.
2014-: Post doc vejleder for Trine K. Sønder, Endothelial (dys)function in patients with type 2 diabetes (EDF-T2D). Endokrinologisk Afd. M, OUH. Registered June 2014
2014 Tutor for Søren Diederichsen OSVAL II project: “ECG pattern of left ventricular hypertrophy or ST-segment deviation in a healthy population: The impact of fasting glucose and other cardiovascular risk factors”. Dept. of Endocrinology, OUH. Passed with 12.
2014: President for the assessment committee for the clinical professorat in interventional cardiology at the Clinical Institute, The Faculty of Health Science, University of Southern Denmark.
2014-: PhD-tutor for Monija Mrgan, “Coronary plaque morphology and plaque progression in patients with newly diagnosed type-2 diabetes mellitus”. Dept. of Cardiology, Hospital of Southvest Jutland, Esbjerg
2015-: PhD-tutor for Mette L. Nielsen, “HOMA index – As a Prognostic Marker in the General Population and as a Marker of Metabolic Phenotype in Type 2 Diabetes Mellitus (HOMAP-Metabolic)” Department of Endocrinology, OUH. Registered January 2015.

Coordination
2006-12:Board member of the Danish Hypertension Society
2007-: Council member of European Society of Hypertension
2008-11:Visualization and exspansion of the Cardiovascular Reseach Unit at Dept. of Internal Medicine, Glostrup University Hospital
2008: Guest editor in Archives of Medical Science: Special issue on hypertension
2009-: Member of the editorial board of Journal Hypertension
2006-: Organizer of more than 20 meetings conserning hypertension including ESH yearly Congress from 2008-2012.
2011: Member of Scientific Committee for 10th International Symposium on Resistance Arteries
2012: President of the Program for Research Education for Heart, Kidney and Circulation at the University of Southern Denmark

Honaries and financial support
2002 Kaj and Allis Bunch-Jensens honorary for contribution to cardiovascular research in Denmark
2005 The AstraZeneca Price from Danish Society of Hypertension
2005 The Hans Ibsen Foundation to strengthen research in hypertension
2008 A 5-year Clinical Research Stipendium from The Novo Nordic Foundation (2,500,000 DKkr).
2008 European Society of Hypertensions two-year Fellowship - Research Grant for Thomas Sehestedt to do his PhD (100,000 Euro).
2008 Support to a Nordic Ph.D. meeting from The joint Committee of the Nordic Medical
Research Councils (NOS-M) (32,000 Euro).
2010 One year Scholar stipendium from Lundbeck Foundation for medical student Thomas Sehested (120,000 DKkr.).
2010 EU funding through Interreg to a research cooperation in the region of Oeresund
with Rigshospitalet, Malmoe Hospital and University of Lund (1,900,000 Euro).
2011 Two one year PhD stipendium (1,050,000 DKkr.) from Novo Nordic Foundation and OUH for Marie K. Blicher and her PhD project: Catheter based Renal denervation in patients with Resistant hypertension – Effects on kidney, Vasculature and Insulin SEnsitivity (REVISE)
2012 A one year PhD stipendium (500,000 DKkr.) and financial support (935,633 DKKr.) from the Region of Southern Denmark for Sara Vikström and her PhD project: SubclinicAl Target Organ damage – a Marker of Individual Cardiovascular Susceptibility (ATOMICS)
2012 Financial support from Odense University Hospital (OUH) (453,500 DKkr.) to the PhD project ATOMICS
2012 European Society of Hypertensions two-year Fellowship - Research Grant for Sara Vikström to do her PhD and start GIRO-TOPIC (100,000 Euro).
2013 A 5-year Clinical Research Stipendium from The Novo Nordic Foundation (2,500,000 DKkr)
2013 Financial support from The Danish Heart Foundation (475,000 DKkr.) and OUH (500,000 DKkr.) for the PhD project REVISE
2013 Financial support from OUH (665,000 DKkr.) for Manan Pareeks PhD project: Detection of Early Atherosclerosis and Arteriosclerosis using Biomarkers and PET/CT (DETECT) in Healthy Controls and Patients with Hypertension, Type 2 Diabetes, or Carotid Artery Stenosis.
2013 A two year PhD stipendium (1,050,000 DKkr.) from Danish Diabetes Academy for Manan Pareek and his PhD project: DETECT
2013 A one year PhD stipendium (500,000 DKkr.) from OUH for Manan Pareek and his PhD project: DETECT
2013 Financial support for a workshop on arterial disease, November 26, 2013 (38.000 DKkr.) from Danish Diabetes Academy (DDA)
2013 Financial support for a PhD course in arterial disease (120.000 DKkr.) from DDA
2014 A three-year Post doc stipendium (1,800,000 DKKr.) for Trine Sønder from DDA.
2014 A two year PhD stipendium (1,050,000 DKkr.) from DDA for Mette Nielsen and her PhD project: HOMA index – As a Prognostic Marker in the General Population and as a Marker of Metabolic Phenotype in Type 2 Diabetes Mellitus (HOMAP-Metabolic)
2014 A one year PhD. stipendium (500.000 DKkr.) from Region of Southern Denmark for the PhD project of Mette Nielsen: HOMAP-Metabolic
2014 Financial support from OUH (288.000 DKkr.) for Mette Nielsens PhD project: HOMAP-Metabolic
2014 A one year PhD. stipendium (1.050.000 DKkr.) from DDA for Thomas Bastholm Olesen and his PhD project: HOMA2 indexed based Phenotyping in Type 2 Diabetes – Cardiovascular Characteristics – An ITT Substudy (HOMAP-CV)
2014 A one year PhD. stipendium (500.000 DKkr.) from Region of Southern Denmark for PhD project of Thomas Bastholm Olesen: HOMAP-CV.
2014 Financial support (200,000 DKK) for the project of Manan Pareek: Sodium Fluoride and Fluorodeoxyglucose Avidity in Carotid Atheroma: Histopathological Correlates (SOFIA) form Aase og Ejnar Danielsen's Foundation.

Publication list
International peer reviewed papers (117, 35 as 1. author and 51 since 2009)
International abstracts (116, 45 as 1. author and 10 as last author)
H-index: 32. Number of citations: 3680 (witout selfcitation 3599).
Average citations per paper: 20

Chaptors in books:
1. Can Microalbuminuria be Considered as an Intermediate End-point? Wachtell K and Olsen MH. 2006.
2. Medicinsk behandling af hypertension. Bang LE, Christensen KL, Olsen MH. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.
3. Midler med virkning på renin-angio¬tensinsystemet. Christensen KL, Olsen MH, Bang LE. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.
4. Diuretika. Olsen MH, Bang LE, Christensen KL. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.

Letters, editorials or reviews:
1. Wachtell K, Olsen MH, Ibsen H. Response to letter. Ann Intern Medicine 2004;141:245.
2. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH; Mogensen CE, Dahlöf B. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Kidney Int 2004;66:S56-8.
3. Höieggen A, Fossum E, Wachtell K, Olsen MH, Reims H, Panish J, Gleim G, Kjeldsen SE, Ibsen H. Hypertension 2002: Year of the LIFE Study. Compendium Series: Cardiovascular 2004;1:4-9.
4. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Response to letter. J Am Coll Card 2005;46:1585-1586
5. Wachtell K, Olsen MH, Dahlöf B, Devereux RB. Primary Prevention of Atrial Fibrillation in Hypertensive Patients: What Is New from the LIFE Trial? In Raviele A ed. Cardiac Arrhythmias 2005. Proceedings of 9th International Workshop on Cardiac Arrhythmias. Springer 2005.
6. Wachtell K and Olsen MH. Is it Time to Change the Definition of Normal Urinary Albumin Excretion? Nat Clin Pract Nephrol. 2008 Dec;4(12):650-1. Practice Point commentary on: Forman JP et al J Am Soc Nephrol 2008.
7. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G; Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008 Oct;26(10):1891-900.
8. Olsen MH, Sehestedt T, Lyngbæk S, Hansen TV, Rasmussen S, Wachtell K, Torp-Pedersen C, Hildebrandt PR, Ibsen H. Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three new Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment? Curr Vasc Pharmacol. 2010 Jan;8(1):134-9.
9. Olsen MH, Sehestedt T, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR. New cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment? Arch Med Sci 2009 in press
10. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27(11):2221-58.
11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308-47.
12. Olsen MH. Assessment of Cardiovascular Risk – The Impact and Future of Non-traditional Cardiovascular Risk Markers. European Cardiology 2010;6(2):10–3
13. Sehestedt T, Olsen MH, Subclinical Organ Damage and Cardiovascular Risk Prediction. Blood Press. 2010;19(3):132-9
14. Olsen MH, Mallion JM, Rahn KH, Erdine S, Viigimaa M, Laurent S, Agabiti-Rosei E, Mancia G, Schmieder RE, Cifkova R, Dominiczak A, Kjeldsen SE, Redon J, Zanchetti A, Nilsson P, Narkiewicz K; ESH Council. Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. J Hypertension 2010;28(7):1593-4.
15. Wachtell K, Olsen MH. Impaired left ventricular systolic function in patients with left ventricular hypertrophy. J Hypertens. 2011;29(11):2068-9.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; ESH Scientific Council, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
17. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.

National papers:
18. Wachtell K, Ibsen H, Olsen MH, Layborn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO. Prevalence of renal artery stenosis in patients with peripheral vascular di¬sease and hypertension. ¬Ugeskrift for Læger 1997;46:6822-24.
19. Olsen MH. Det kardiovaskulære Metaboliske Syndrom. Lægemagasinet 1998;6:12-14.
20. Olsen MH, Ibsen H, Mogensen CE. Mikroalbuminuri. Ugeskrift for Læger 2009;25:2097-2100
21. Olsen MH, Sehestedt T, Prescott E. Den kardiovaskulære risikoprofil og antihypertensiv behandling. Ugeskrift for Læger 2009;24:2008-11
22. Olsen MH, Jeppesen J, Larsen ML. Hypertension og det metaboliske syndrom. Ugeskrift for Læger 2009;25:2107-09
23. Olsen MH. Nye kardiovaskulære risikofaktorer. BestPractice 2010;1:28.
24. Buus NH, Mathiassen ON, Andersen UB, Olsen MH. Kateter-baseret renal denervering. Ugeskr Laeger. 2012 Mar 19;174(12):789.

Original papers:
25. Olsen NV, Olsen MH, Fogh-Andersen N, Feldt-Rasmussen B, Kamper A, Plum I, Strandgaard S, Leyssac PP. Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. Clinical Science 1993; 84:237-42.
26. Wachtell K, Ibsen H, Olsen MH, Layborn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO. Prevalence of renal artery stenosis in patients with peripheral vascular di¬sease and hypertension. J Hum Hypertens 1996;10:83-85.
27. Olsen NV, Olsen MH, Bonde J, Kanstrup IL, Plum I, Strand¬gaard S, Leyssac PP. Dopamine natriure¬sis in salt-repleted, water-loaded humans: a dose-response study. British Journal of Clinical Pharmacology 1997;43:509-520.
28. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. Influence of non-steady state during isoglycemic hyperinsulinemic clamp in hypertension. A LIFE substudy. Blood Pressure 1999;8:207-213.
29. Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S. Relative Influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE substudy. J Hypertens 2000;18:75-81.
30. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Blood Pressure 2000;9:132-139.
31. Olsen MH, Wachtell K, Hermann KL, Bella JN, Andersen UB, Dige-Petersen H, Rokkedal J, Ibsen H. Maximal exercise capacity is closely related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Am J Hypertens 2001;14:1205-1210
32. Olsen MH, Wachtell K, Aalkjaer C, Devereux RB, Dige-Petersen H, Ibsen H. Endothelial Dysfunction in Resistance Arteries is Related to High Blood Pressure and Circulating Low Density Lipoproteins in Previously Treated Hypertension. Am J Hypertens 2001;14:861-867.
33. Olsen MH, Wachtell K, Aalkjaer C, Dige-Petersen H, Rokkedal J, Ibsen H. Vasodilatory capacity and vascular structure in patients with longstanding hypertension. A LIFE substudy. Am J Hypertens 2002;15(5):398-404.
34. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J 2002;144(3):530-7.
35. Olsen MH, Wachtell K, Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB, Borch-Johnsen K, Ibsen H. A Blood Pressure Independent Association between Glomerular Albumin Leakage and Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hum Hypertens 2002;16:591-5
36. Olsen MH, Wachtell K, Hermann KL, Bella JN, Dige-Petersen H, Rokkedal J, Ibsen H. Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. Blood Pressure 2002;11:1-8
37. Olsen MH, Hjerkinn E, Wachtell K, Høieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Julius S, Ibsen H. Are Left Ventricular Mass, Geometry and Function Related to Vascular Changes and/or Insulin Resistance in Longstanding Hypertension. A LIFE Substudy. J Hum Hypertens 2003;17:305-11
38. Olsen MH, Wachtell K, Meyer C, Hove JD, Palmieri V, Dige-Petersen H, Rokkedal J, Hesse B, Ibsen H. Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension and left ventricular hypertrophy. A LIFE substudy. J Hum Hypertens 2004;18:445-452
39. Olsen MH, Wachtell K, Palmieri V, de Simone G, Dige-Petersen H, Ibsen H, Devereux RB, Rokkedal J. Is Inappropriate Left Ventricular Mass Related to Neuro-hormonal Factors and/or Vascular Changes in Hypertension. A LIFE Substudy. J Hum Hypertens 2004;18:437-443
40. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Albuminuria Predicts Cardiovascular Events Independently of Left Ventricular Mass in Hypertension. A LIFE Substudy. J Hum Hypertens 2004;18:453-459
41. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal proBrain Natriuretic Peptide Predict Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Substudy. J Hypertens 2004; 22(8):1597-1604.
42. Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, Papademetriou V, Nieminen MS, Rokkedal J, Dahlöf B, Devereux RB. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004; 94(8):1076-1080.
43. Olsen MH, Wachtell K, Bella JN, Gerdts E, Palmieri V, Nieminen M, Smith G, Kjeldsen SE, Dahlöf B, Ibsen H, Devereux RB. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95(1):132-136.
44. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Hjerkinn E, Bang LE, Wiinberg N, Christensen MK, Rokkedal J, Hildebrandt P, Palmieri V, Frandsen E, Kjeldsen SE, Dige-Petersen H, Ibsen H, Jensen LT. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertens 2005; 19(4):301-7.
45. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. Opposite Effects of Losartan and Atenolol on Natriuretic Peptides in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. J Hypertension 2005; 23(5):1083-90.
46. Olsen MH, Fossum E, Wachtell K, Høieggen A, Hjerkinn E, Kjeldsen SE, Dige-Petersen H, Julius S, Ibsen H. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23(4):891-8.
47. Olsen MH, Wachtell K, Neland K, Rokkedal J, Ibsen H, Dige-Petersen H. Losartan and not Atenolol Reduce Carotid Artery Hypertrophy in Essential Hypertension. A LIFE Substudy. Blood Pressure 2005;14(3):177-83.
48. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Aortic Valve Sclerosis and Albuminuria Independently Predict Cardiovascular Events in Hypertension. A LIFE Substudy. Am J Hypertension 2005;18:1430-36.
49. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. Nt-pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:1-7
50. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. High sensitivity C-reactive protein is related to cardiovascular damage, but not independently of cardiovascular risk factors. J Hypertens 2006;24(4):655-61
51. Olsen MH, Wachtell K, Dahlof B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. J Hum Hypertens 2006;20(6):460-4
52. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24(4):775-81
53. Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlof B, Hildebrandt PR. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006;24(8):1531-9
54. Olsen MH, Hansen TW, Christensen MK, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide, but not high sensitivity C-reactive protein improves cardiovascular risk prediction in the general population. European Heart Journal 2007;28:1374-81
55. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and gender. J Hypertension 2008;26(1):26-34
56. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. J Hum Hypertens 2008;22:634-40.
57. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. New risk markers may change the HeartScore risk-classification significantly in one fifth of the population. J Hum Hypertens 2008;23(2):105-112.
58. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The prognostic importance of hemoglobin in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE Study. Am Heart J. 2009 Jan;157(1):177-84
59. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Losartan has Positive Effects on Lipid Metabolism Compared to Atenolol in Patients with Hypertension and Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hypertens 2009;27(3):567-74
60. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Kjeldsen SE, Omvik P, Nieminen MS, Dahlöf B, Okin PM, Devereux RB. Changes in subclinical organ damage versus Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment. A LIFE Sustudy. J Hypertens 2011;29(5):997-1004.
61. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Borch-Johnsen K, Rokkedal J, Ibsen H, Devereux RB. Urine Albunin/Creatinine Ratio and Echocardiographic Left Ventricular Structure and Function in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy. Am Heart J 2002;143(2):319-26.
62. Bella JN, Wachtell K, Boman K, Palmieri V, Papademetriou V, Gerdts E, Aalto T, Olsen MH, Olofsson M, Dahlöf B, Roman MJ, Devereux RB. Relation of Left Ventricular Geometry and Function to Aortic Root Dilatation in Patients with systemic Hypertension and Left Ventricular Hypertrophy: The LIFE Study. Am J Cardiol 2002;89:337-341.
63. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Jern S, Julius S, Kjeldsen SE, Nieminen MS, Omvik P, Okin PM, Mogensen CE, Borch-Johnsen K, Ibsen H. Microalbuminuria in Hypertensive Patients Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hypertens 2002;20(3):405-12.
64. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB. Change in Systolic Left Ventricular Performance After Three Years of Antihypertensive Treatment: The LIFE Study. Circulation 2002;106(2);227-32.
65. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
66. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, Wachtell K, for the LIFE study group. Less Sudden Cardiac Death in Diabetics Treated with Losartan – Data From the LIFE Trial. Lancet 2003;362:619-20.
67. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. Ann Internal Med 2003;139:601-9
68. Hildebrandt P, Boesen M, Olsen MH, Wachtell K, Groenning B. N-terminal Pro Brain Natriuretic Peptide in Arterial Hypertension - a Marker for Left Ventricular Dimensions and Prognosis. Eur J Heart Fail. 2004;6:313-7
69. Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims H, Ibsen H, Julius S, Kjeldsen SE. Long-Term Plasma Catecholamine Levels in Patients with Hypertension and Left Ventricular Hypertrophy Treated with Losartan or Atenolol. ICARUS, a LIFE Substudy. J Hum Hypertens 2004;18:375-380
70. Wiinberg N, Bang LE, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Rokkedal J, Ibsen H, Devereux RB. 24-hour Ambulatory Blood Pressure and Urinary Albumin Excretion in Patients with ECG Determined Left Ventricular Hypertrophy: The LIFE Study. J Hum Hypertens 2004;18:391-396
71. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Snapinn S, Wedel H. Does Albuminuria Predict Cardiovascular Outcome on Treatment with Losartan Versus Atenolol in Patients with Hypertension and Left Ventricular Hypertrophy? A LIFE substudy. J Hypertens 2004; 22(9):1805-1811.
72. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Snapinn S, Wedel H. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int Suppl 2004;(92):S56-S58.
73. Andersen UB, Olsen MH, Dige-Petersen H, Ibsen H. Exercise blood pressure is related to insulin resistance in subjects with two hypertensive parents. Blood Press. 2003;12(5-6):314-8
74. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198-202.
75. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):705-11
76. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-9
77. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, Ibsen H, Kjeldsen SE, Dahlof B.Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension. 2005;46(3):492-9
78. Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, Holm S, Hesse B. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy.Am J Cardiol. 2005;96(12):1692-8
79. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.Diabetes Care. 2006;29(3):595-600
80. Christensen MK, Olsen MH, Wachtell K, Bang LE, Tuxen C, Hjerkinn E, Rokkedal J, Frandsen E, Hildebrandt P, Kjeldsen SE, Ibsen H, Dige-Petersen H. Effect of Losartan versus Atenolol on Circulating Collagen Markers and the Prognostic Value of Changes in these Markers. A LIFE Substudy. Blood Press 2006;15:198-206.
81. Fossum E, Olsen MH, Hoieggen A, Wachtell K, Reims HM, Kjeldsen SE, Ibsen H, Wan Y, Julius S. Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens (Greenwich). 2006;8(3):169-73.
82. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de ZD. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007;25(4):871-6.
83. Bang LE, Wiinberg N, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Ibsen H. Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 2007;16(6):392-7.
84. Wachtell K, Okin PM, Olsen MH, Dahlof B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007;116(7):700-5
85. de SG, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007;21(8):625-32
86. Smebye ML, Iversen EK, Hoieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlof B. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Am J Cardiol 2007;100(5):855-9
87. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, Dahlof B. Combination of the Electrocardiographic Strain Pattern and Albuminuria for the Prediction of New-onset Heart Failure in Hypertensive Patients: The LIFE Study. Am J Hypertens 2008;21:273-279
88. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol. 2008;21(4):566-9.
89. Pedersen SA, Galatius S, Olsen MH, Madsen BK, Madsen JK, Nielsen OW. High prevalence of risk factors in coronary artery disease in EUROPA gives HOPE for ACE inhibitors after PEACE. Cardiology 2008;111(1):63-7.
90. Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2008;15(5):594-8.
91. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Kjeldsen SE, Devereux RB. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis. 2009;19(9):634-40.
92. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Petersen C, Olsen MH. Which markers of subclinical organ damage to measure in subjects with high normal blood pressure? J Hypertens 2009;27(6):1165-71.
93. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp Petersen C, Olsen MH. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens 2009;27(12):2351-7
94. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Petersen C, Hildebrandt PR, Olsen MH. Risk stratification is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31(7):883-91
95. Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH,Okin PM, Palmieri V, Rokkedal JE, Devereux RB.In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010;19(3):169-75.
96. Wiik BP, Larstorp AC, Høieggen A, Kjeldsen SE, Olsen MH, Ibsen H, Lindholm L, Dahlöf B, Devereux RB, Okin PM, Wachtell K.Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study. Am J Hypertens. 2010;23(8):845-51
97. Søraas CL, Wachtell K, Okin PM, Dahlöf B, Devereux RB, Tønnessen T, Kjeldsen SE, Olsen MH. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. Blood Press. 2010;19(3):145-51.
98. Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010;28(7):1541-6
99. Sehested TS, Hansen TW, Olsen MH, Abildstrøm SZ, Rasmussen S, Ibsen H,Torp-Pedersen C, Madsbad S, Jeppesen J. Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2010;17(4):486-90.
100. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbæk S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Internal Medicine 2010;268(3):296-308.
101. Larstorp ACK, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlô B, Kjeldsen SE, Wachtell K. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study. J Hum Hypertens 2010 May [Epub ahead of print]
102. Sehestedt T, Lyngbæk S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Jørgensen T, Haugaard SB, Olsen MH. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011;216(1):237-43.
103. Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. Thromb Res Accepted 30 Oct 2011.
104. Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Schutte AE. N-terminal prohormone B-type natriuretic peptide and cardiovascular function in Africans and Caucasians: the SAfrEIC study. Heart, Lung and Circulation Accepted
105. Redon J, Olsen MH, Cooper RS, Zurriaga O, Martinez-Beneito MA, Laurent S,Cifkova R, Coca A, Mancia G. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32(11):1424-31.
106. Fourie CM, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, Schutte R,Schutte AE. Soluble Urokinase Plasminogen Activator Receptor (suPAR) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study. Inflammation 2012; 35(1):221-231.
107. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan,candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623-35.
108. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Petersen C, Olsen MH. Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage? J Hypertens 2012;30(3):513-21.
109. Kruger R, Schutte R, Huisman HW, Argraves WS, Rasmussen LM, Olsen MH, Schutte AE. NT-proBNP is associated with fibulin-1 in Africans: the SAfrEIC study. Atherosclerosis 2012;222(1):216-21.
110. Ruwald AH, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH. Losartan- versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. J Hypertens 2012;30(6):1252-9.
111. Jeppesen JL, Nielsen SJ, Torp-Pedersen C, Hansen TW, Olsen MH, Berg ND,Linneberg A, Madsbad S, Fenger M. Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. Am J Hypertens. 2012;25(10):1095-100
112. Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM,Dahlöf B, Kjeldsen SE, Wachtell K. Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Hypertension 2012;60(2)347-53.
113. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K. Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study. Am J Hypertens. 2012:25(10):1101-9
114. Greve AM, Olsen MH, Bella JN, Lønnebakken MT, Gerdts E, Okin PM, Palmieri V,Boman K, Nieminen MS, Omvik P, Dahlöf B, Devereux RB, Wachtell K. Contrasting Hemodynamic Mechanisms of Losartan- vs. Atenolol-Based Antihypertensive Treatment: A LIFE Study. Am J Hypertens. 2012;25(9):1017-23.
115. Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM,Kjeldsen SE, Dahlöf B, Wachtell K. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Blood Press. 2012;21(1):6-11
116. Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012;29(4):479-87.
117. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens. 2012;30(10):1928-36.
118. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Sans S, Olsen MH. The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk. Hypertension 2012;60(5):1117-1123.
119. Kruger R, Schutte R, Huisman HW, Olsen MH, Schutte AE. NT-proBNP and potential vascular calcification in Black and Caucasian African men: the SAfrEIC study. Ethn Dis. 2012;22(4):398-403.
120. Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904-11
121. De Marco M, Gerdts E, Casalnuovo G, Migliore T, Wachtell K, Boman K, Dahlof B, Olsen MH, Kizer JR, Devereux RB, De Simone G, Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study. Am J Hypertens. 2013;26(4):567-73.
122. Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, Schutte AE. NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study. PLoS One. 2013;8(3):e58506.
123. Diederichsen SZ, Gerke O, Olsen MH, Lambrechtsen J, Sand NP, Nørgaard BL, Mickley H, Diederichsen AC. Coronary artery calcification and ECG pattern of left ventricular hypertrophy or strain identify different healthy individuals at risk. J Hypertens. 2013;31(3):595-600.
124. Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167(3):781-5.
125. Hvidt KN, Olsen MH, Holm J-C, Ibsen H. Aortic stiffness in obese children and adolescents: comparison of two distance measures of carotid-femoral pulse wave velocity. Artery Research 2013;7:186-193.
126. Hvidt KN, Olsen MH, Holm J-C, Ibsen H. Aortic stiffness in obese children and adolescents: the potential bias of a tape distance measurement of carotid-femoral pulse wave velocity. Artery Research 2013;7:234-237.
127. Hvidt KN, Olsen MH, Holm JC, Ibsen H. Obese Children and Adolescents Have Elevated Nighttime Blood Pressure Independent of Insulin Resistance and Arterial Stiffness. Am J Hypertens. 2014;32(7):1470-7.
128. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A, Pechère-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J,Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky JI Jr, Jacobs L, Spiering W,Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML,Staessen JA; on behalf of the European Network Coordinating research on Renal Denervation (ENCOReD) Consortium. Eligibility for Renal Denervation: Experience at 11 European Expert Centers. Hypertension 2014.
129. Greve SV, Blicher MK, Blyme A, Sehestedt T, Hansen TW, Rassmusen S, Vishram JK, Ibsen H, Torp-Pedersen C, Olsen MH. Association between albuminuria, atherosclerotic plaques, elevated pulse wave velocity, age, risk category and prognosis in apparently healthy individuals. J Hypertens. 2014;32(5):1034-41.
130. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Salomaa V, Sans S, Ferrieres J, Tamosiunas A, Söderberg S, McElduff P, Arveiler D, Pajak A, Olsen MH. Do other cardiovascular risk factors influence the impact of age on the association between blood pressure and mortality? The MORGAM Project. J Hypertens. 2014;32(5):1025-33.
131. Kruger R, Rasmussen LM, Argraves WS, Eugen-Olsen J, Nielsen OW, Blyme A, Willenheimer R, Wachtell K, Olsen MH. Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study). PLoS One. 2014;9(7):e101522.
132. Hvidt KN, Olsen MH, Ibsen H, Holm JC. Effect of changes in BMI and waist circumference on ambulatory blood pressure in obese children and adolescents. J Hypertens. 2014 Jul;32(7):1470-7.
133. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M,Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Arfan Ikram M, Völzke H,Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; for the PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2014 Nov 2, PubMed PMID: 25416041.
134. Hvidt KN, Olsen MH, Holm JC, Ibsen H. Response to the Association Between Obesity and Nighttime Blood Pressure in Obese Children by Adjustments of Insulin Resistance and Arterial Stiffness. Am J Hypertens. 2014 Oct 8, PubMed PMID: 25298175.
135. Nielsen ML, Pareek M, Gerke O, Diederichsen SZ, Greve SV, Blicher MK, Sand NP, Mickley H, Diederichsen AC, Olsen MH. Uncontrolled hypertension is associated with coronary artery calcification and electrocardiographic left ventricular hypertrophy: a case-control study. J Hum Hypertens. 2014 Oct 2, PubMed PMID: 25273860.
136. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T,Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K,Salomaa V, Sans S, Ferrieres J, Dallongeville J, Söderberg S, Arveiler D, Wagner A, Tunstall-Pedoe H, Drygas W, Olsen MH; MORGAM Project. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014;9(9)
137. Sørensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 2014;237(1):60-6.

Fingerprint Dive into the research topics where Michael Hecht Olsen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 52 Similar Profiles
Urokinase Plasminogen Activator Receptors Medicine & Life Sciences
Left Ventricular Hypertrophy Medicine & Life Sciences
Population Medicine & Life Sciences
Brain Natriuretic Peptide Medicine & Life Sciences
Type 2 Diabetes Mellitus Medicine & Life Sciences
Fasting Medicine & Life Sciences
Confidence Intervals Medicine & Life Sciences
Vascular Stiffness Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2011 2019

Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study

Larstorp, A. C. K., Stokke, I. M., Kjeldsen, S. E., Hecht Olsen, M., Okin, P. M., Devereux, R. B. & Wachtell, K., Oct 2019, In : Blood Pressure. 28, 5, p. 317-326

Research output: Contribution to journalJournal articleResearchpeer-review

Left Ventricular Hypertrophy
Risk Reduction Behavior
Losartan
Double-Blind Method
Electrocardiography

Baseline findings of the population-based, randomized, multifaceted Danish cardiovascular screening trial (DANCAVAS) of men aged 65-74 years

Lindholt, J. S., Rasmussen, L. M., Søgaard, R., Lambrechtsen, J., Steffensen, F. H., Frost, L., Egstrup, K., Urbonaviciene, G., Busk, M., Olsen, M. H., Hallas, J. & Diederichsen, A. C., Jun 2019, In : The British journal of surgery. 106, 7, p. 862-871

Research output: Contribution to journalJournal articleResearchpeer-review

Population
Iliac Aneurysm
Thoracic Aortic Aneurysm
Abdominal Aortic Aneurysm
Hyperlipidemias

Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial

Oxlund, C. S., Pareek, M., Rasmussen, B. S. B., Vaduganathan, M., Biering-Sørensen, T., Byrne, C., Almarzooq, Z., Olsen, M. H. & Bhatt, D. L., Jul 2019, In : The American Journal of Medicine. 132, 7, p. 840-846

Research output: Contribution to journalJournal articleResearchpeer-review

Body Mass Index
Safety
Acute Coronary Syndrome
Diabetes Mellitus
15 Downloads (Pure)

Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis

Krishnan, A., Finkelstein, E. A., Kallestrup, P., Karki, A., Olsen, M. H. & Neupane, D., Oct 2019, In : The Lancet Global Health. 7, 10, p. e1367-e1374

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
File
Nepal
Cost-Benefit Analysis
Quality-Adjusted Life Years
United Nations
Health

Fixed-dose combination antihypertensive medications

Benjamin, I. J., Kreutz, R., Olsen, M. H., Schutte, A. E., Lopez-Jaramillo, P., Frieden, T. R., Sliwa, K., Lackland, D. T. & Brainin, M., 24. Aug 2019, In : Lancet. 394, 10199, p. 637-638

Research output: Contribution to journalComment/debateResearchpeer-review

Activities 2006 2014

"Hypertension - Number one killer in the world"

Michael Hecht Olsen (Guest lecturer)
3. Dec 2014

Activity: Talks and presentationsGuest lectures, external teaching and course activities at other universities

High an Low Blood pressure. CV risk, BP goals, Antihypertensive Treatment"

Michael Hecht Olsen (Lecturer)
13. Nov 2014

Activity: Talks and presentationsGuest lectures, external teaching and course activities at other universities

Flow mediated vasodilatation in the brachial artery samt Echocardiografic left atrium size and -function

Michael Hecht Olsen (Lecturer)
20. Nov 201221. Nov 2012

Activity: Talks and presentationsTalks and presentations in private or public companies

Press / Media

ANDRE NAVNE

Michael Hecht Olsen

04/10/2018

1 Media contribution

Press/Media: Press / Media

Aktuelle navne

Michael Hecht Olsen

03/10/2018

1 Media contribution

Press/Media: Press / Media

Aktuelle navne

Michael Hecht Olsen

03/10/2018

1 Media contribution

Press/Media: Press / Media

Tiltrædelsesseminar

Michael Hecht Olsen

02/10/2018

1 Media contribution

Press/Media: Press / Media

Tiltrædelsesseminar

Michael Hecht Olsen

02/10/2018

1 Media contribution

Press/Media: Press / Media